Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07142356 · ClinicalTrials.gov registry record · Phase 2
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
A Phase 2 study of Uncontrolled Hypertension, sponsored by Retension Pharmaceuticals..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 3
- Study locations
NCT07142356: Recruiting Phase 2 study of Uncontrolled Hypertension, sponsored by Retension Pharmaceuticals..
NCT07142356 is a Phase 2 study of Uncontrolled Hypertension that is actively recruiting participants, run by Retension Pharmaceuticals.. The registered enrollment target is 280 participants, below the 736-participant average among 10 other Uncontrolled Hypertension trials with a reported enrollment target (62% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07142356, a Phase 2 study of Uncontrolled Hypertension, is actively recruiting participants, sponsored by Retension Pharmaceuticals..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to learn if the drug RT-001 works to reduce high blood pressure (hypertension) in adults. It will also learn about the safety of RTN-001. The main questions it aims to answer are: Does RTN-001 lower blood pressure in patients who have uncontrolled hypertension? What medical problems do participants have when taking RTN-001? Researchers will compare RTN-001 to a placebo (a look-alike substance that contains no drug) to see if RTN-001 works to treat uncontrolled hypertension. Participants will: Take RTN-001 or a placebo every day for 12 weeks Visit the clinic about once every 2 weeks for checkups and tests Keep a diary of their symptoms and all medications that they take including RTN-001
Primary Outcome
The difference in the mean change in pre-dose office-seated systolic blood pressure in patients with uncontrolled hypertension after 4 weeks of treatment with RTN-001 versus placebo.
Conditions Studied
Interventions
- DRUG RTN-001
- DRUG Matching placebo control
Study Locations (3)
North Carolina
- Retensiion Clinical Site - Monroe
South Carolina
- Retension Clinical Site - Charleston
Virginia
- Retension Clinical Site - Vienna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2025-10-31 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What NCT07142356 shows while recruiting
NCT07142356 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 736-participant average among 10 other Uncontrolled Hypertension trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Uncontrolled Hypertension appearing as the primary indexed condition, and to 2 interventions - of which RTN-001 is the first listed.
NCT07142356 reports a single indexed study location in North Carolina, South Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT07142356 about?
NCT07142356 is a clinical study titled "A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension". The goal of this clinical trial is to learn if the drug RT-001 works to reduce high blood pressure (hypertension) in adults. It will also learn about the safety of RTN-001. The main questions it aims to answer are: Does RTN-001 lower blood pressure in patients who have uncontrolled hypertension? Wh...
What is the current status of trial NCT07142356?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2025-10-31. Estimated completion is 2027-05.
What conditions does trial NCT07142356 study?
This clinical trial studies the following conditions: Uncontrolled Hypertension.
What interventions are being tested in trial NCT07142356?
The interventions under investigation include: RTN-001 (DRUG), Matching placebo control (DRUG).
Who is sponsoring clinical trial NCT07142356?
This trial is sponsored by Retension Pharmaceuticals., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07142356 being conducted?
This trial has 3 study locations across North Carolina, South Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uncontrolled Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07142356's enrollment target sits among peer trials
280 5th of 10 higher than 6 of 10 other Uncontrolled Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uncontrolled Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity
RECRUITING · NA
-
Renal Pelvic Denervation Pilot Trial
RECRUITING · NA
-
Wearable Evaluation of Ambulatory Readings for Blood Pressure
RECRUITING · NA
-
Remote Hypertension Management for Black Patients
RECRUITING · NA
-
Community Health Workers Reduce Social Barriers That Affect the Health of Patients With High Blood Pressure and Diabetes.
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI